$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

$abvc Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023025554 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$128.3K	$589.0K	$969.8K
YoY Change	399.89%	65.54%	172.56%
Cost Of Revenue	$60.24K	$265.4K	$286.4K
YoY Change	3070.32%	5114.34%	5527.01%
Gross Profit	$68.04K	$323.6K	$683.4K
YoY Change	186.35%	-7.74%	94.85%
Gross Profit Margin	53.04%	54.94%	70.47%
Selling, General & Admin	$1.273M	$1.961M	$6.068M
YoY Change	-78.37%	-82.26%	-45.1%
% of Gross Profit	1870.7%	605.97%	887.89%
Research & Development	$335.0K	$1.496M	$2.693M
YoY Change	-6.79%	49.01%	168.32%
% of Gross Profit	492.36%	462.26%	394.14%
Depreciation & Amortization	$6.493K	$6.440K	$23.80K
YoY Change	20.02%	97.55%	98.49%
% of Gross Profit	9.54%	1.99%	3.48%
Operating Expenses	$1.974M	$3.457M	$15.80M
YoY Change	-68.37%	-71.33%	31.03%
Operating Profit	-$1.906M	-$3.133M	-$15.11M
YoY Change	-69.35%	-73.24%	29.12%
Interest Expense	$56.66K	-$358.8K	$294.0K
YoY Change	91.88%	1202.72%	-1167.42%
% of Operating Profit
Other Income/Expense, Net	$8.954K	$63.86K	-$400.2K
YoY Change	-39.13%	-87.78%	-176.56%
Pretax Income	-$1.897M	-$3.538M	-$15.51M
YoY Change	-69.27%	-68.44%	38.39%
Income Tax		$962.9K	$797.8K
% Of Pretax Income
Net Earnings	-$1.824M	-$4.864M	-$16.42M
YoY Change	-70.04%	-62.12%	27.92%
Net Earnings / Revenue	-1421.74%	-825.81%	-1693.5%
Basic Earnings Per Share	-$0.06		-$0.52
Diluted Earnings Per Share	-$0.06	-$0.15	-$0.50
COMMON SHARES
Basic Shares Outstanding	33.08M shares	32.63M shares	31.66M shares
Diluted Shares Outstanding	33.08M shares		30.15M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.213M	$161.1K	$161.1K
YoY Change	-56.89%	-97.29%	-97.29%
Cash & Equivalents	$1.135M	$85.27K	$85.27K
Short-Term Investments	$78.01K	$75.80K	$75.80K
Other Short-Term Assets	$1.005M	$1.457M	$1.457M
YoY Change	-50.01%	-25.29%	-25.29%
Inventory			$0.00
Prepaid Expenses
Receivables	$124.1K	$98.33K	$855.7K
Other Receivables	$520.0K	$513.8K	$513.8K
Total Short-Term Assets	$3.480M	$2.987M	$2.987M
YoY Change	-56.43%	-68.96%	-68.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$571.6K	$574.0K	$1.735M
YoY Change	-71.15%	9.15%	-13.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$849.8K	$842.1K	$842.1K
YoY Change	-6.02%	-9.72%	-9.72%
Other Assets	$3.489M	$4.291M	$4.291M
YoY Change	192.38%	275.62%	275.62%
Total Long-Term Assets	$7.255M	$6.868M	$6.868M
YoY Change	77.87%	68.63%	68.63%
TOTAL ASSETS
Total Short-Term Assets	$3.480M	$2.987M	$2.987M
Total Long-Term Assets	$7.255M	$6.868M	$6.868M
Total Assets	$10.73M	$9.855M	$9.855M
YoY Change	-11.04%	-28.05%	-28.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$2.763M	$2.910M	$3.279M
YoY Change	73.08%	123.68%	98.97%
Deferred Revenue		$10.99K
YoY Change
Short-Term Debt	$902.0K	$1.894M	$1.894M
YoY Change	-43.97%	15.47%	15.47%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.075M	$5.820M	$5.820M
YoY Change	38.52%	57.61%	57.61%
LONG-TERM LIABILITIES
Long-Term Debt	$3.207M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$718.9K	$799.8K	$799.8K
YoY Change	-30.98%	-29.56%	-29.56%
Total Long-Term Liabilities	$3.926M	$799.8K	$799.8K
YoY Change	276.85%	-29.56%	-29.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.075M	$5.820M	$5.820M
Total Long-Term Liabilities	$3.926M	$799.8K	$799.8K
Total Liabilities	$9.000M	$6.619M	$6.757M
YoY Change	93.98%	37.11%	39.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$56.73M	-$54.90M
YoY Change		42.68%
Common Stock	$33.08K	$32.86K
YoY Change		13.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$9.100M	$9.100M
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity	$1.670M	$3.099M	$3.099M
YoY Change
Total Liabilities & Shareholders Equity	$10.73M	$9.855M	$9.855M
YoY Change	-11.04%	-28.05%	-28.05%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.824M	-$4.864M	-$16.42M
YoY Change	-70.04%	-62.12%	27.92%
Depreciation, Depletion And Amortization	$6.493K	$6.440K	$23.80K
YoY Change	20.02%	97.55%	98.49%
Cash From Operating Activities	-$1.498M	-$461.1K	-$7.398M
YoY Change	-49.98%	-77.58%	-2.62%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$90.00	$119.7K
YoY Change	-100.0%		-783.95%
Acquisitions
YoY Change
Other Investing Activities		-$83.20K	-$1.602M
YoY Change		100.05%	103.18%
Cash From Investing Activities		-$83.28K	-$1.722M
YoY Change		100.24%	113.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$3.664M
YoY Change
Debt Paid & Issued, Net	$1.000M
YoY Change
Cash From Financing Activities	$2.207M	-253.5K	$4.014M
YoY Change		-105.96%	-59.84%
NET CHANGE
Cash From Operating Activities	-$1.498M	-461.1K	-$7.398M
Cash From Investing Activities		-83.28K	-$1.722M
Cash From Financing Activities	$2.207M	-253.5K	$4.014M
Net Change In Cash	$400.2K	-797.9K	-$5.173M
YoY Change	-112.96%	-137.02%	-425.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.498M	-$461.1K	-$7.398M
Capital Expenditures	$0.00	$90.00	$119.7K
Free Cash Flow	-$1.498M	-$461.2K	-$7.518M
YoY Change	-48.38%	-77.57%	-0.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2022	abvc	Operating Sublease Income Related Parties OperatingSubleaseIncomeRelatedParties		usd
CY2022	us-gaap	Interest Income Securities Us Treasury And Other Us Government InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40700
CY2022	dei	Entity Registrant Name EntityRegistrantName	ABVC BioPharma, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0014658
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	44370 Old Warm Springs Blvd
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
CY2022	dei	Entity Address Country EntityAddressCountry	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
CY2022	dei	City Area Code CityAreaCode	510
CY2022	dei	Local Phone Number LocalPhoneNumber	-668-0881
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	ABVC
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	18851957	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33080740	shares
CY2022	dei	Auditor Name AuditorName	WWC, P.C.
CY2022	dei	Auditor Firm AuditorFirmId	1171
CY2022	dei	Auditor Location AuditorLocation	San Mateo, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85265	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5828548	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1306463	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	736667	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	98325	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	280692	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	757343	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	145399	usd
CY2022Q4	abvc	Prepayment For Longterm Investments PrepaymentForLongtermInvestments	513819	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	25975	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	75797	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	108147	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	150235	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	528354	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2987247	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	7653782	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573978	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	525881	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1161141	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1471899	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	842070	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	932755	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	117110	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	981912	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	135135	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	119309	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	58838	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	41157	usd
CY2022Q4	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	2838578	usd
CY2021Q4	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	1153155	usd
CY2022Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	1141378	usd
CY2021Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	818183	usd
CY2022Q4	us-gaap	Assets Assets	9855475	usd
CY2021Q4	us-gaap	Assets Assets	13698033	usd
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	1893750	usd
CY2021Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	1640000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2909587	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1300803	usd
CY2022Q4	abvc	Advance From Customers AdvanceFromCustomers	10985	usd
CY2021Q4	abvc	Advance From Customers AdvanceFromCustomers	10985	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	369314	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	347100	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	635893	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	393424	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5819529	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3692312	usd
CY2022Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	7980	usd
CY2021Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	10580	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	791827	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1124799	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6619336	usd
CY2021Q4	us-gaap	Liabilities Liabilities	4827691	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32857329	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32857329	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	32857	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	28926	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	67907479	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	58113667	usd
CY2022Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	1354440	usd
CY2021Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	2257400	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54904439	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38481200	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-517128	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-539660	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3098585	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8843653	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	137554	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	26689	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3236139	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8870342	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9855475	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13698033	usd
CY2022	us-gaap	Revenues Revenues	969783	usd
CY2021	us-gaap	Revenues Revenues	355797	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	286415	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	5086	usd
CY2022	us-gaap	Gross Profit GrossProfit	683368	usd
CY2021	us-gaap	Gross Profit GrossProfit	350711	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6067545	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5746119	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2693457	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1003805	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7036778	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5306755	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	15797780	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	12056679	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15114412	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-11705968	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	187817	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	43196	usd
CY2022	us-gaap	Interest Expense InterestExpense	293968	usd
CY2021	us-gaap	Interest Expense InterestExpense	227210	usd
CY2022	abvc	Rent Income RentIncome	107150	usd
CY2021	abvc	Rent Income RentIncome	134576	usd
CY2021	abvc	Operating Sublease Income Related Parties OperatingSubleaseIncomeRelatedParties	4800	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	110125	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-7446	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-259463	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	426316	usd
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-269844	usd
CY2022	us-gaap	Other Income OtherIncome	-24149	usd
CY2021	us-gaap	Other Income OtherIncome	22409	usd
CY2021	us-gaap	Interest Income Securities Us Treasury And Other Us Government InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment	360898	usd
CY2021	abvc	Repayment Of Notes Payable RepaymentOfNotesPayable	107400	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	236498	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	350000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-400184	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	495141	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15514596	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11210827	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	797778	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	825024	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-16312374	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-12035851	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	110865	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	802962	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16423239	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-12838813	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22532	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-25200	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16445771	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12864013	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31664660	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25053522	shares
CY2022	us-gaap	Profit Loss ProfitLoss	-16312374	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-12035851	usd
CY2022	us-gaap	Depreciation Depreciation	23799	usd
CY2021	us-gaap	Depreciation Depreciation	11993	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7036778	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	5306755	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-269844	usd
CY2022	abvc	Increasedecrease In Inventory Allowance For Valuation Losses IncreasedecreaseInInventoryAllowanceForValuationLosses	-25975	usd
CY2022	abvc	Provision For Doubtful Account ProvisionForDoubtfulAccount	-184589	usd
CY2021	abvc	Government Grant Income GovernmentGrantIncome	360898	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-32350	usd
CY2022	abvc	Investment Loss InvestmentLoss	110125	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	864802	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	824199	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	614166	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	120980	usd
CY2022	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	238092	usd
CY2021	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-357276	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	837014	usd
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	595037	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	25830	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-23044	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1608784	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-173151	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1085	usd
CY2021	abvc	Proceeds Fromrepayments Of Short Term Borrowings From Third Parties ProceedsFromrepaymentsOfShortTermBorrowingsFromThirdParties	4265	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4013925	usd
CY2022	abvc	Increasedecrease In Security Deposit Received IncreasedecreaseInSecurityDepositReceived	2600	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	242469	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-317358	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7398391	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7597719	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	107547	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	119692	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17503	usd
CY2022	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	1601992	usd
CY2021	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	680916	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1721684	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-805966	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3663925	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11119452	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9995550	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-67337	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	850429	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	306836	usd
CY2021	abvc	Repayment Of Shortterm Loan RepaymentOfShorttermLoan	100000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-28021	usd
CY2022	us-gaap	Fiscal Period FiscalPeriod	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Fiscal Year</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5173487	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1563844	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6565215	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5001371	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1391728	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6565215	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	285465	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	333873	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	1600	usd
CY2021	abvc	Common Shares Issued For Debt Conversion CommonSharesIssuedForDebtConversion	2693548	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2662067	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10269023	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1728590	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	2693548	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	902960	usd
CY2021	abvc	Stock Issued During Period Value Share Based Compensation Services StockIssuedDuringPeriodValueShareBasedCompensationServices	2675205	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-12035851	usd
CY2021	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-25200	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8870342	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3663925	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4891888	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	902960	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1241930000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-16312374	usd
CY2022	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-22532	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3236139	usd
CY2022	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583 pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company.
CY2017Q1	abvc	Percentage Of Common Shares Issued And Outstanding PercentageOfCommonSharesIssuedAndOutstanding	0.73	pure
CY2022	abvc	Company Reported CompanyReported	16312374	usd
CY2022Q4	us-gaap	Capital Capital	2832282	usd
CY2022Q3	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	7398391	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2016Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	360000000	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85265	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5828548	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1306463	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	736667	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We perform ongoing credit evaluation of our customers and requires no collateral. An allowance for doubtful accounts is provided based on a review of the collectability of accounts receivable. We determine the amount of allowance for doubtful accounts by examining its historical collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit losses may differ from our estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable	0.7189	pure
CY2021	us-gaap	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable	0.3338	pure
CY2022	abvc	Total Revenues TotalRevenues	0.9322	pure
CY2021	abvc	Total Revenues TotalRevenues	0.4624	pure
CY2022	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
CY2020	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
CY2022	abvc	Labour Pension Fund Percentage LabourPensionFundPercentage	0.06	pure
CY2022	abvc	Percentage Of Monthly Contributions PercentageOfMonthlyContributions	0.06	pure
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	13031	usd
CY2021	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	11375	usd
CY2022	abvc	Stock Based Compensation For Employees StockBasedCompensationForEmployees	1241930	usd
CY2021	abvc	Stock Based Compensation For Employees StockBasedCompensationForEmployees	2675205	usd
CY2022	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	5794848	usd
CY2021	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	2631550	usd
CY2022	abvc	Beneficial Conversion Feature BeneficialConversionFeature	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Beneficial Conversion Feature</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	abvc	Defined Benefit Plan Funded Percentages DefinedBenefitPlanFundedPercentages	0.50	pure
CY2022	abvc	Milestone Payments Royalty Percentage MilestonePaymentsRoyaltyPercentage	0.12	pure
CY2018Q4	abvc	Co Dev Agreement Description CoDevAgreementDescription	On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	96725	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	84620	usd
CY2021Q4	abvc	Allowance For Inventory Valuation And Obsolescence Loss AllowanceForInventoryValuationAndObsolescenceLoss	155370	usd
CY2021Q4	us-gaap	Inventory Gross InventoryGross	25975	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3878435	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3840352	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3304457	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3314471	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	573978	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	525881	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23799	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11993	usd
CY2022Q4	us-gaap	Land And Land Improvements LandAndLandImprovements	361193	usd
CY2021Q4	us-gaap	Land And Land Improvements LandAndLandImprovements	400091	usd
CY2022	abvc	Schedule Of Ownership Percentages Of Investee Table Text Blocks ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ownership percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Accounting</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of related party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">treatments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.22</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.22</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Genepharm Biotech Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.92</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.92</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.03</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.03</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">BioFirst Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21.77</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21.77</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rgene Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28.85</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28.85</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b> </b></p>
CY2022Q4	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	842070	usd
CY2021Q4	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	932755	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	842070	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	932755	usd
CY2021	abvc	Purchase Additional Shares PurchaseAdditionalShares	317000	shares
CY2021Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	618150	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.2885	pure
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.2885	pure
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-269844	usd
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.25
CY2021Q3	abvc	Convertible Promissory Note ConvertiblePromissoryNote	2500000	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1111112	shares
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1893750	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1640000	usd
CY2021Q3	abvc	Principal Amount principalAmount	7500000	twd
CY2021Q3	abvc	Principal Amount principalAmount	243750	usd
CY2021Q3	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2022Q3	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	7500000	twd
CY2022Q3	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	243750	usd
CY2022Q3	abvc	Loan Agreement LoanAgreement	P1Y
CY2017Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2019-07-18
CY2021Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0168	pure
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	20000000	twd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	650000	usd
CY2021Q3	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.02	pure
CY2019Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000000	usd
CY2019Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.05	pure
CY2020Q2	abvc	Received Loan Amount ReceivedLoanAmount	350000	usd
CY2020Q4	abvc	Received Loan Amount ReceivedLoanAmount	350000	usd
CY2020Q2	abvc	Loan From Paycheck Protection Program LoanFromPaycheckProtectionProgram	124400	usd
CY2020Q2	abvc	Forgiven Amount Percentage Used For Payroll ForgivenAmountPercentageUsedForPayroll	0.60	pure
CY2021Q1	abvc	Loan From Paycheck Protection Program LoanFromPaycheckProtectionProgram	132331	usd
CY2021Q1	abvc	Forgiven Amount Percentage Used For Payroll ForgivenAmountPercentageUsedForPayroll	0.60	pure
CY2021Q1	abvc	Promissory Note Description PromissoryNoteDescription	The loan was granted pursuant to a promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note.
CY2021Q1	abvc	Loan From Paycheck Protection Programs LoanFromPaycheckProtectionPrograms	104167	usd
CY2021Q1	abvc	Forgiven Amount Percentage Used For Payroll ForgivenAmountPercentageUsedForPayroll	0.60	pure
CY2021Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.01	pure
CY2019Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.12	pure
CY2019Q1	abvc	Working Capital WorkingCapital	3000000	twd
CY2019Q1	abvc	Working Capital WorkingCapital	106800	usd
CY2022Q4	us-gaap	Other Notes Payable OtherNotesPayable	0	usd
CY2021Q4	us-gaap	Other Notes Payable OtherNotesPayable	0	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	8592	usd
CY2020Q1	us-gaap	Unsecured Debt UnsecuredDebt	100000	usd
CY2020Q3	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.015	pure
CY2021Q3	us-gaap	Interest And Fee Income Other Loans InterestAndFeeIncomeOtherLoans	102272	usd
CY2022	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	0	usd
CY2021	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	0	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	757343	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	145399	usd
CY2022Q4	abvc	Due From Related Parties Noncurrents DueFromRelatedPartiesNoncurrents	1141378	usd
CY2021Q4	abvc	Due From Related Parties Noncurrents DueFromRelatedPartiesNoncurrents	818183	usd
CY2021	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.12	pure
CY2021	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	33520	usd
CY2021	us-gaap	Accounts Receivable Noncurrent Accrued Interest Writeoff AccountsReceivableNoncurrentAccruedInterestWriteoff	13701	usd
CY2021Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	1889	usd
CY2022Q2	abvc	Related Parties Transactions RelatedPartiesTransactions	the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.
CY2022	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	500000	usd
CY2022Q4	us-gaap	Percentage Of Debt Hedged By Interest Rate Derivatives PercentageOfDebtHedgedByInterestRateDerivatives	0.065	pure
CY2022Q4	us-gaap	Due From Employees Noncurrent DueFromEmployeesNoncurrent	112822	usd
CY2021Q4	us-gaap	Due From Employees Noncurrent DueFromEmployeesNoncurrent	124972	usd
CY2020Q2	abvc	Aggregated Amount AggregatedAmount	150000	usd
CY2020Q2	us-gaap	Prepaid Interest PrepaidInterest	150000	usd
CY2022	abvc	Schedule Of Related Party Transactions Amount Due To Related Party ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">BioFirst Corporation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">188,753</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">BioFirst (Australia)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">275,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">132,443</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>AsiaGene</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,017</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>YuanGene</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,205</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">The Jiangs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Due to shareholders</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151,450</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168,131</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">635,893</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">393,424</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	abvc	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	635893	usd
CY2021Q4	abvc	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	393424	usd
CY2022Q4	abvc	Outstanding Principal And Accrued Interest OutstandingPrincipalAndAccruedInterest	151450	usd
CY2021Q4	abvc	Outstanding Principal And Accrued Interest OutstandingPrincipalAndAccruedInterest	168131	usd
CY2022	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	21378	usd
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	22779	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2400	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	800	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2400	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	800	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	795378	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-187055	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	795378	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-187055	usd
CY2022Q4	abvc	Total Provision For Income Taxe TotalProvisionForIncomeTaxe	-797778	usd
CY2021Q4	abvc	Total Provision For Income Taxe TotalProvisionForIncomeTaxe	186255	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	709961	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	741390	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5866623	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	2801363	usd
CY2021	us-gaap	Investment Tax Credit InvestmentTaxCredit	698187	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	213482	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	213482	usd
CY2022Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	6576584	usd
CY2021Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	4240940	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6459474	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3259028	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	117110	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	981912	usd
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50000	shares
CY2021Q2	us-gaap	Share Price SharePrice	5
CY2021Q1	abvc	Agreement Description AgreementDescription	In January 2021, WallachBeth entered into a consulting agreement with the Company pursuant to which the Company engaged WallachBeth to conduct due diligence and research work with respect to the Company.
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1111112	shares
CY2020Q4	abvc	Convertible Promissory Note Value ConvertiblePromissoryNoteValue	2500000	usd
CY2021Q3	abvc	Description Of Public Offering DescriptionOfPublicOffering	On August 5, 2021, the Company closed its public offering (the “Public Offering”) of 1,100,000 units (the “Units”), with each Unit consisting of one share of the Company’s common stock, one Series A warrant (the “Series A Warrants”) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the “Series B Warrants,” and together with the Series A Warrants, the “Public Warrants”) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the “SEC”) on April 8, 2021 (as amended, the “Original Registration Statement”), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the “S-1MEF,” together with the Original Registration Statement, the “Registration Statement”). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000.
CY2021Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4244452	usd
CY2021Q4	abvc	Aggregate Common Stock Shares AggregateCommonStockShares	673605	shares
CY2021Q4	abvc	Consulting Fees ConsultingFees	1478590	usd
CY2022Q1	abvc	Consulting Fees ConsultingFees	4296763	usd
CY2022Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	75000	shares
CY2022Q1	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	169500	usd
CY2022Q1	us-gaap	Share Price SharePrice	2.26
CY2022Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	2000000	shares
CY2022Q2	abvc	Gross Proceeds GrossProceeds	4220000	usd
CY2022Q2	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	556075	usd
CY2022Q2	abvc	Warrants Term WarrantsTerm	P5Y
CY2022Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	2000000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.45
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	545182	shares
CY2020Q4	abvc	Conversion Price ConversionPrice	2
CY2020Q4	abvc	Consulting Fees ConsultingFees	1090361	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	545182	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1280002	shares
CY2021Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	761920	shares
CY2022Q2	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0279	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0113	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8386	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0851	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	761920	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1280002	shares
CY2022	abvc	Fair Value Of Options Granted FairValueOfOptionsGranted	1.63	usd
CY2021	abvc	Fair Value Of Options Granted FairValueOfOptionsGranted	2.09	usd
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	1241930	usd
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	2675205	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16423239	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12838813	usd
CY2022	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	31664600
CY2021	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	25053522
CY2022	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	31664600
CY2021	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	25053522
CY2022	abvc	Loss Per Share Basic LossPerShareBasic	-0.52
CY2021	abvc	Loss Per Share Basic LossPerShareBasic	-0.51
CY2022	abvc	Loss Per Share Diluted LossPerShareDiluted	-0.52
CY2021	abvc	Loss Per Share Diluted LossPerShareDiluted	-0.51
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1161141	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1471899	usd
CY2022Q4	abvc	Operating Lease Liabilitiescurrents OperatingLeaseLiabilitiescurrents	369314	usd
CY2021Q4	abvc	Operating Lease Liabilitiescurrents OperatingLeaseLiabilitiescurrents	347100	usd
CY2022Q4	abvc	Operating Lease Liabilitienoncurrent OperatingLeaseLiabilitienoncurrent	791827	usd
CY2021Q4	abvc	Operating Lease Liabilitienoncurrent OperatingLeaseLiabilitienoncurrent	1124799	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	358576	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	335208	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	358576	usd
CY2021	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	335208	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M23D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0149	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0139	pure
CY2022Q4	abvc	Operating Leases Future Minimum Payment Due In Two Years OperatingLeasesFutureMinimumPaymentDueInTwoYears	374478	usd
CY2022Q4	abvc	Operating Leases Future Minimum Payment Due In Three Years OperatingLeasesFutureMinimumPaymentDueInThreeYears	389613	usd
CY2022Q4	abvc	Operating Leases Future Minimum Payment Due In Four Years OperatingLeasesFutureMinimumPaymentDueInFourYears	348837	usd
CY2022Q4	abvc	Operating Leases Future Minimum Payment Due In Five Years OperatingLeasesFutureMinimumPaymentDueInFiveYears	56916	usd
CY2022Q4	abvc	Operating Leases Future Minimum Payment Due OperatingLeasesFutureMinimumPaymentDue	1169844	usd
CY2022Q4	abvc	Interest Portion Of Minimum Lease Payments Sale Lease Back Transaction InterestPortionOfMinimumLeasePaymentsSaleLeaseBackTransaction	8703	usd
CY2022Q4	abvc	Present Value Of Future Minimum Lease Payment Sale Leaseback Transactions PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions	1161141	usd
CY2021Q4	abvc	Prepayment For Longterm Investments PrepaymentForLongtermInvestments		usd
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24420526	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24420526	shares
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss		usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2021	abvc	Increasedecrease In Inventory Allowance For Valuation Losses IncreasedecreaseInInventoryAllowanceForValuationLosses		usd
CY2021	abvc	Provision For Doubtful Account ProvisionForDoubtfulAccount		usd
CY2022	abvc	Government Grant Income GovernmentGrantIncome		usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
CY2021	abvc	Investment Loss InvestmentLoss		usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable		usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2021	abvc	Increasedecrease In Security Deposit Received IncreasedecreaseInSecurityDepositReceived		usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2022	abvc	Repayment Of Notes Payable RepaymentOfNotesPayable		usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2022	abvc	Proceeds Fromrepayments Of Short Term Borrowings From Third Parties ProceedsFromrepaymentsOfShortTermBorrowingsFromThirdParties		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	abvc	Common Shares Issued For Debt Conversion CommonSharesIssuedForDebtConversion		usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods		usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials		usd
CY2022Q4	abvc	Allowance For Inventory Valuation And Obsolescence Loss AllowanceForInventoryValuationAndObsolescenceLoss		usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross		usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Investment Tax Credit InvestmentTaxCredit		usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability		usd
CY2021Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent		usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
CY2022Q4	abvc	Operating Leases Future Minimum Payment Due There After OperatingLeasesFutureMinimumPaymentDueThereAfter		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001173313

Files In Submission

Name	View Source	Status
abvc-20221231_cal.xml	Edgar Link	unprocessable
abvc-20221231_lab.xml	Edgar Link	unprocessable
0001213900-23-025554-index-headers.html	Edgar Link	pending
0001213900-23-025554-index.html	Edgar Link	pending
0001213900-23-025554.txt	Edgar Link	pending
0001213900-23-025554-xbrl.zip	Edgar Link	pending
abvc-20221231.xsd	Edgar Link	pending
f10k2022ex10-6_abvcbiopharma.htm	Edgar Link	pending
f10k2022ex21-1_abvcbiopharma.htm	Edgar Link	pending
f10k2022ex3-2_abvcbiopharma.htm	Edgar Link	pending
f10k2022ex31-1_abvcbiopharma.htm	Edgar Link	pending
f10k2022ex31-2_abvcbiopharma.htm	Edgar Link	pending
f10k2022ex32-1_abvcbiopharma.htm	Edgar Link	pending
f10k2022ex32-2_abvcbiopharma.htm	Edgar Link	pending
f10k2022_abvcbiopharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
abvc-20221231_def.xml	Edgar Link	unprocessable
abvc-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_abvcbiopharma_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

2023 Q1 Form 10-K Financial Statement

#000121390023025554 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC ABVC BIOPHARMA, INC. Stock $abvc

2023 Q1 Form 10-K Financial Statement

#000121390023025554 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc